Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Ose as many sneets as necessary)						
Sheet	1	of	1			

Complete if Known				
Application Number	10/559,982			
Filing Date	February 2, 2006			
First Named Inventor	Ruggero Fariello			
Group Art Unit	1617			
Examiner Name	Sahar JAVANMARD			
Confirmation No.	6583			
Attorney Docket No.	373987-011US (102895)			

U.S. PUBLISHED DOCUMENTS					
Examiner Initials*	Cite No.1	U.S. Publication Do Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
	A10	US-5,502,079		Dostert et al.	03-26-1996

	FOREIGN PATENT DOCUMENTS							
Examiner		For	eign Patent Docu	ment	Date of		Transla	tion ²
Initials*	No. 1	Office	Number	Kind Code (if known)	Publication of Cited Document MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Yes	No
	B1							

Examin Cite		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s),		Translation ²	
er Initials*			Yes	No	
	C106	ANONYMOUS: "Newron Releases Positive Preliminary Phase II Data for Salfinamide in Parkinson's Disease" PRESS RELEASE OF 01-09-2003, Retrieved from the Internet. "Items in the control of			
	C107	Chazot, P., 2001, "Salfinamide, Newron Pharmaceuticals," Current Opinion in Invest. Drugs, 2(6): 809-813			
	C108	Maj, R. et al., 1999, "PNU-141774E, A Combined MAO-B and Glutamate Release Inhibitor, is Effective in Animal Models of Parkinson's Disease," Society for Neuroscience, Vol. 25, p. 1599			

15107351.1.BUSINESS

Examiner	/Sahar Javanmard/	Date Considered	09/13/2009
Digitature			00/10/2000

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered Include copy of this form with next communication to applicant.